**Phase I Program**

Note: Other Phase 1 Studies may be open at the Knight, please click here to view.

---

**No Known Mutations**

- **IRB#9902**
  Nivolumab or Nivolumab + Ipilimumab in Advanced or Metastatic Solid Tumors

- **IRB#11638**
  ACP-196 and Pembrolizumab in Subjects with Advanced Head and Neck Squamous Cell Carcinoma

- **IRB#11688**
  LOXO-101 in Adult Patients with Solid Tumors

- **IRB#11804**
  Lenvatinib + Keytruda in Subjects with Advanced Solid Tumors

- **IRB#12008**
  PDR001 in Patients with Advanced Malignancies

- **IRB#15678**
  FPA008 + Nivolumab in Subjects with Advanced Solid Tumors

- **IRB#16198**
  TTI-621 in subjects with Nivolumab in Patients with Advanced Melanoma

- **IRB#16732**
  BMS-986175, Nivolumab and/or Ipilimumab in Subjects with Advanced Solid Tumors

- **IRB#16804**
  DCC-3014 in subjects with advanced malignancies

- **IRB#17521**
  SNDX-6352 with or without Durvalumab in Patients with Unresectable, Recurrent, Locally-Advanced, or Metastatic Solid Tumors

---

**Study coming soon**

- **IRB# 19277**
  Study coming soon

- **IRB# 19388**
  A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

- **IRB# 19390**
  A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176

- **IRB# 20399**
  Study coming soon

---

**Key**

- Open for Enrollment
- In Development
- Enrollment on Hold

---

12/23/2019

http://www.ohsu.edu/research/rda/so/knight.php
Phase I Program

Note: Other Phase 1 Studies may be open at the Knight, please click here to view.

**Tumor Mutation Burden - High**

**NTRK, ROS1, ALK gene rearrangement**

**Fusion-NTRK (previously treated)**

**RET Mutations**

**Fusion Proteins Specific**

**BRD Amplifications Specific**

**MYC Amplifications Specific**

**AR Amplifications Specific**

**Melanoma**

**IRB 20920 Study coming soon**

**IRB 20920 Study O2A coming soon**

**IRB 20920 Study O2B coming soon**

**IRB 20920 Study O2C coming soon**

---

**IRB#18788**

Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

**IRB#15206**

Entrectinib in Patients with Advanced or Metastatic Solid Tumors

**IRB# 17674**

LOXO-195 in fusion-NTRK (previously treated) solid tumors

**IRB#16676**

BLU-667 in thyroid cancer, non-small cell lung cancer and advanced solid tumors

**IRB#18164**

A Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity

**IRB# 16702**

A Phase I/IIa Trial With BMS-986158 as Monotherapy or in Combination with Nivolumab in Subjects with Selected Advanced Solid Tumors

---

12/23/2019

http://www.ohsu.edu/research/rda/so/knight.php